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cancer
S. Foulds, C.H. Wakefield, M. Giles, J. Gillespie, J.F. Dye & P.J. Guillou
Academic Surgical Unit, Imperial College ofScience, Technology and Medicine, St Mary's Hospital Medical School,
London W2 JNY, UK.
Summary mRNA for the suppressive epitope of plSE was found to be present in 24 of 30 samples of human
colorectal cancer and in all four specimens of gastric cancer. mRNA for p1SE was seldom seen in non-
malignant colonic or gastric mucosa but, when present, was associated with inflammatory or pre-malignant
conditions of the digestive tract. Synthetic peptides derived from the conserved plSE sequence were found to
suppress some aspects of the immune response implicated in anti-tumour activity. These data suggest that a
plSE-related material with immunomodulatory properties is elaborated within human tumours, either by the
tumour itself or as a normal component of the endogenous anti-tumour reaction.
In vitro, combination of cytokines and cytotoxic cell precur-
sors result in the generation of a variety of effector cell
functions with anti-tumour activity. Unfortunately the in vivo
clinical application of these concepts in humans suffering
from malignant disease has met with only limited success,
and this only in patients with selected tumours such as
malignant melanoma and renal cell cancer (West et al., 1987;
Rosenberg et al., 1989; Guillou, 1991). Explanations for this
are manifold but one possibility which we, and others, have
focused upon in recent years is that tumours may be able to
subvert any useful immunologically based endogenous anti-
tumour reaction by the elaboration of soluble moieties which
possess immunosuppressive properties (Ebert et al., 1987;
Guillou et al., 1989a, b; Somers et al., 1991).
A variety of murine and human tumours have been found
to exert immunosuppressive effects in vitro. Some studies
have associated these effects with the presence of the retro-
viral envelope protein pl5E (Snyderman & Cianciolo, 1984).
pl5E is encoded by the env gene of the murine and feline
leukaemia viruses. There is 73% homology in a 26-amino
acid stretch between p1SE and gp2l of the human T-cell
leukaemia viruses HTLV-1 and HTLV-2. This 26-amino acid
sequence contains a string of 17 amino acids (Table I) which
has previously been discovered in the murine B16 melanoma
(Leong et al., 1988) and in human head and neck cancers
(Tan et al., 1987). Synthetic peptides of this 17-amino acid
string can impair a number of lymphocyte- and monocyte-
mediated reactions both in vivo (Nelson et al., 1989) and in
vitro (Harrell et al., 1986; Oostendorp et al., 1992). Such
peptides have also been reported to inhibit the production of
interleukin-2 (IL-2) (Nelson & Nelson, 1990) a defect which
is common in patients suffering from advanced cancer (Mon-
son et al., 1986).
In this study we aimed to determine whether or not pl5E-
related material might explain the in vivo and in vitro
immunosuppression seen in patients with colorectal and gast-
ric tumours (Monson et al., 1987; Guillou, 1989). We pre-
pared a synthetic oligonucleotide probe corresponding to a
10-amino acid sequence which is incorporated into the 17-
amino acid immunosuppressive peptide of retroviral p1SE.
This probe was used for the detection of endogenous mRNA
coding for plSE-related material in preparations of human
primary colorectal and gastric cancers. In addition, because
the function of this shorter 10-amino acid sequence is un-
known, we have also manufactured synthetic peptides corre-
sponding to this sequence in order to determine their effects
on some aspects of immune function in vitro. The results of
these investigations reveal that mRNA for plSE-related
material is highly expressed in most human colorectal and
gastric cancers and that peptides encoded by this oligo-
nucleotide are potently suppressive of some but not all
aspects of the cellular immune response.
Materials and methods
RNA preparation and analysis
Samples of tumour were obtained from 31 patients undergo-
ing colorectal resection for a diagnosis of colorectal cancer.
Of these the diagnosis was histologically substantiated in 30
patients, the remaining diagnosis being that of a stricture of
the ascending colon due to Crohn's disease. This latter resec-
tion was performed on the radiological presumption that the
stricture was a carcinoma so the data obtained for this
specimen are also presented. Tumour samples were also
obtained from fresh operative gastrectomy specimens during
resectional surgery in four patients suffering from endo-
scopically and biopsy-proven carcinoma of the stomach. The
demographic and pathological staging data on the patients
with colorectal and gastric cancer are shown in Table II.
Simultaneously with the acquisition of the tumour samples,
whenever possible, samples of normal colonic or gastric
mucosa were removed from the proximal resection margin, at
least 10 cms from the tumour. The samples were obtained
fresh from the operating room, freed of debris, snap-frozen
in liquid nitrogen within 10 min of surgical removal, and
stored at - 70'C until RNA extraction.
Total cellular RNA was prepared using the RNAzol B
method (Biogenesis, Bournemouth, UK). Briefly, the tissue
was homogenised in RNAzol followed by extraction of the
RNA in chloroform and precipitation in isopropanol. The
Table I Amino acid sequences of peptides which possess varying
degrees of identity with retroviral plSE
p15E LQNRRGLDLLFLKEGGL
(Stewart et al., 1986)
FG-10
FG-17
QNRRGLDLLF
LQNRRGLDLLFLKEGGL
CKS-17 LQNRRGLDLLFLKEGGL-BSA
(Cianciolo et al., 1985)
HTLV QNRRGLDLLF
CD4
IFN-a
LLLFIGLGIFFCVRCCRH
LQNRRALILLAQMGRIS
TNF-a WLNRRANALLANGVELR
REPASKE QNRLALDYLL
(Cianciolo et al., 1985)
(Rothman et al., 1990)
(Ruegg & Strand, 1990)
(Sprang & Eck, 1992)
(Repaske et al., 1985)
Correspondence: P.J. Guillou, Academic Surgical Unit, Level 8,
Clinical Sciences Building, St. James's University Hospital, Leeds
LS9, UK.
Received 7 February 1993; and in revised form 6 May 1993.
Br. J. Cancer (1993), 68, 610-616 '." Macmillan Press Ltd., 1993pl5E IN GASTROINTESTINAL CANCER 611
Table II Demographic data on patients whose tumours were
studied
Mean age+s.d. M:F ratio Staging
Colorectal 63.5± 11.2 years 20:10 Dukes' A - 1
cancer Dukes' B- 13
Dukes' C- 11
Dukes' D- 5
Gastric cancer 65.3± 7.1 years 2:2 All node-positive
(TI-3, N1-2)
RNA was then washed in 75% ethanol and resuspended in
RNAase-free water by incubation at 60°C for 10min.
The detection of p15E mRNA was accomplished by
Northern blot hybridization. The isolated RNA was denatur-
ed by glyoxal treatment and subjected to electrophoresis in a
1.4% agarose gel. The RNA was then transferred onto
Hibond-N+ membranes (Amersham, Amersham, UK) in
10 x SSC buffer (Sigma, Dorset, UK). Membranes were then
baked at 80°C for 2 h and prehybridised at 57°C in hybridisa-
tion buffer (3.3 x SSC, S x Denhardt's solution (Sigma),
0.5% SDS (Sigma), 150 tg ml1l sonicated salmon sperm
DNA (Sigma) and 0.4% EDTA (Sigma)). Hybridisation was
conducted overnight at 57°C using 3'-end 32P-labelled oligo-
nucleotide probes (British Biotechnology, Oxford, UK). The
specific probe for plSE-related material corresponded to the
10 amino acid sequence common to both pl5E and gp2l of
HTLV (Table I). The sequence of this probe was as follows:
S'-GAA TAG AAT ATC TAG GCC CCG TCT GTT TGG-3'
Two controls for the pl5E probe, one with a three nucleo-
tide substitution and one with a six nucleotide substitution,
were also prepared. These control probes did not cross hybri-
dise with the p15E probe under the hybridisation conditions
used. Simultaneous controls for the RNA extraction proce-
dure were also run using standard P-actin probes (British
Biotechnology, Oxford, UK). After hybridisation the mem-
branes were washed for 10 min at room temperature in
2 x SSC and 0.2% SDS followed by two washes for 40 min
at 57°C in 0.1 x SSC and 0.2% SDS. Membranes were auto-
radiographed with Fuji RX X-ray film (Wardray Ltd., Sur-
rey, UK) at - 70°C.
Synthetic peptides
Peptides derived from the conserved p1SE sequence (Table I)
were synthesised by a standard technique on an Applied
Biosystems 431A peptide synthesizer (Foster City, CA, USA)
and cleaved in trifluoroacetic acid/5% phenol. The crude
peptides were purified by gel filtration and reverse-phase
chromatography and lyophilised from 20% acetic acid.
Purity was assessed by amino acid analysis and reverse-phase
chromatography to be greater than 95%. The amino-acid
sequences of the peptides used in these experiments were as
follows:
Peptide FG-17: LQNRRGLDLLFLKEGGL
Peptide FG-10: QNRRGLDLLF
The 10-amino acid sequence is a component of the 17-amino
acid immunosuppressive peptide of retroviral p1SE. This pep-
tide has been extensively characterised as CKS-17 (Cianciolo
et al., 1985). The studies quoted used multiple modifications
of the 17-amino acid sequence, none of which exhibited
immunosuppressive activity. We therefore did not repeat
these experiments here. For the purposes of the present
experiments, the peptides were not coupled to human serum
albumin and were dissolved in culture medium directly for in
vitro use.
Leukocyte preparation
Venous blood was obtained from healthy members of the
laboratory staff and collected in Acid-citrate-dextrose (ACD,
Baxter, Thetford, UK). Periphal blood mononuclear cells
were obtained from this blood by centrifugation over Lym-
phoprep (Nycomed, Oslo, Norway), washed three times in
phosphate buffered saline (PBS, ICN-Flow laboraties, Irvine,
UK), and resuspended in tissue culture medium (TCM) con-
sisting of RPMI 1640 medium (ICN-Flow laboratories)
supplemented with 10% heat-inactivated foetal calf serum
(Globepharm, Surrey, UK) and Hybrimax antibiotic/anti-
mycotic solution (Sigma).
Neutrophils were obtained by Dextran sedimentation of
ACD-anticoagulated blood at 37°C for 1 h. The leukocyte-
rich population was decanted, washed in glucose/gelatine-
containing PBS (PBS-G) and then resuspended in PBS-G in
preparation for measurement of the neutrophil oxidative
burst as described below.
Lymphocyte activation studies
The effects of the synthetic p15E peptides on lymphocyte
activation were examined using the two-way mixed lympho-
cyte reaction (MLR) or stimulation with interleukin-2 (IL-2,
EuroCetus, Amsterdam, The Netherlands) or anti-CD3
(Seralab Ltd., Sussex, UK) monoclonal antibody. Peripheral
blood mononuclear cells were cultured in 96-well plates at a
final concentration of 106 cells ml-' in a volume of 200ftl/
well and all cultures were performed in quintuplicate. To
these cultures was added either 10 ng ml-' of anti-CD3
monoclonal antibody or 1000 units ml-' of recombinant
human IL-2, together with varying amounts of FG-10 and
FG-17 to give final concentrations ranging from 10-5 M to
101 M. Control cultures contained the appropriate mitogen
without any peptide. The plates were incubated in a humid-
ified atmosphere of 5% CO2 at 37°C for 4 days before being
pulsed with 0.5 ,uCi [3H]-thymidine (Amersham) per well
overnight and then harvested by filtration onto glass-fibre
paper. The incorporated radioactivity was determined by
liquid scintillation spectrophotometry (Packard 1900CA
Tricarb).
Two-way mixed-lymphocyte cultures were also performed
in 96-well plates in a volume of 150itl per well containing
5 x 105ml-' of peripheral blood mononuclear cells from
each of two normal donors. These cultures were incubated
for 120 h at 37°C and then 50jil ofpeptides under study were
added to the wells to give final concentrations of 10-5 M to
10-10 M. Culture was then continued for a further 20 h before
being pulsed with 0.5ftCi [3H]-Thymidine per well overnight
and harvested as described above. All cultures were estab-
lished in quintuplicate wells.
LAK cell assay
The influence of synthetic peptides on the induction of
lymphokine-activated killer (LAK) cells was examined in
bulk cultures of PBMC containing 2 x 106 cells per ml in
TCM in 6-well plates containing 8 x 106 cells. These were
activated by adding 1,000 units mll recombinant human
IL-2. FG-10 and FG-17 were added at a final concentration
of 10-6 M. To some wells no peptides were added, partly to
act as controls and partly to provide LAK cells for studies of
the potential influence of these peptides on the cytotoxicity
assay. These bulk cultures were incubated for 4 days at 37°C
and then harvested for use as effector cells in the cytotoxicity
assay. This was performed as previously described (Dye et
al., 1991). Briefly, 3 x 106 COLO 320 target cells were
labelled with 100IfCi of 51Cr-Na2CrO4 (ICN-Flow) for 1 h.
After washing in phosphate buffered saline 104 51Cr-labelled
target cells in 100;Ll TCM were added to the wells of 96-well
plates. One hundred effector cells from the bulk cultures were
also added to these wells in triplicate at effector:target cell
ratios ranging from 100:1 down to 3:1. The percentage
specific 5'Cr-release at each effector:target cell ratio was then
calculated according to the formula:
Specific 5'Cr release=
Experimental -Spontaneous release x 100%
Maximal - Spontaneous release
where spontaneous release is that from wells to which no
effector cells have been added and maximum release was that612 S. FOULDS et al.
observed when the effector cells were replaced by a detergent
solution. The data are expressed as Area Under the Curve
(AUC) units as previously described in detail (Dye et al.,
1991).
Immunoglobulin production
PBMC isolated as described above were cultured as for the
proliferation assays but instead of IL-2 or anti-CD3 anti-
body, 10jig ml' of Pokeweed mitogen (Sigma) was added.
Peptides at the concentrations described were added to these
cultures, control wells containing no peptide. The plates were
incubated at 37°C for 10 days following which 100l1 super-
natant were harvested from each well and the total immuno-
globulin content of the supernatant measured using an
ELISA technique. Briefly, a 96-well Immunoplate (ICN-
Flow) was coated with goat anti-human polyvalent immuno-
globulin (Sigma) in a carbonate-bicarbonate buffer overnight
at 4°C. The wells were washed with a washing solution (1%
Tween (Sigma) in PBS) three times and blocked with 1%
bovine serum albumin (Sigma) in PBS for 1 h at 37°C. The
blocking solution was aspirated from the wells and the test
supernatants added. The plate was incubated for 1 h at 37°C
and washed three times with washing solution. Alkaline
phosphatase conjugated goat anti-human polyvalent immuno-
globulin (Sigma) was then added to the wells and incubated
at 37°C for 1 h, washed three times, and alkaline phosphatase
substrate (Sigma) added to the wells. The substrate was
allowed to develop colour for 30 min and the reaction was
then stopped using IN Sulphuric Acid. The absorbence was
measured on a Titertek Multiscan ELISA reader (ICN-Flow)
using a 405 nm filter and the data analysed using Titersoft
Software (ICN-Flow).
Neutrophil oxidative burst
Peripheral blood granulocytes isolated from healthy donors
as described above were incubated either alone or with FG-
10 or FG-17 for 2 h at 37°C and their oxidative burst in
response to activation with Zymosan or Phorbol-Myristic
Acetate (PMA) was measured using a modification of a
previously described technique (Bass et al., 1986; Wakefield
et al., 1993). Briefly, 1.5 x 106 granulocytes ml-I were incu-
bated in 5 mM 2,7-Dichlorofluorescein diacetate (Eastman
Kodak ) for 15 min at 37TC. One ml aliquots of this suspen-
sion were then added either to 1 ml of Dulbecco's phosphate-
buffered saline containing glucose and gelatine (DPBS-G), or
DBPS-G containing 200 ngml-' PMA or DPBS-G contain-
ing zymosan. The intensity of neutrophil fluorescence was
measured by flow cytometry at 45 min. The data acquired for
granulocytes incubated with the peptides were compared with
those granulocytes to which no peptide had been added.
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Results
Hybridisation analysis ofhuman endogenous piSE-related
transcripts
Northern blot analyses for plSE-related mRNA were per-
formed on 30 individual samples of colorectal cancer, one
sample of colonic mucosa subsequently shown to be afflicted
by Crohn's disease, and 24 samples of macroscopically 'nor-
mal' colonic mucosa from 24 of the colorectal cancer resec-
tional specimens. Of these, positive blots for plSE-related
mRNA were identified in 24 of the colorectal cancer speci-
mens whereas positive blots were obtained for only four of
the 24 specimen of 'normal' colonic mucosa from the same
patients. (pl5E-related positivity in cancer tissue vs that in
'normal' mucosa, d.f. = 1, x2 = 21.4, P<0.001). Typical
examples of plSE-related positive samples of colorectal
cancer, together with negative blots from the correspondingly
macroscopically 'normal' mucosa are shown in Figure 1.
There was no statistically significant relationship between the
incidence of p1SE-related positivity to the stage of progres-
sion of the colorectal cancer as determined by Dukes' classi-
fication (Table III). The specimen of tissue obtained from the
single patient who histologically was found to have Crohn's
disease was also positive for plSE-related mRNA. Interest-
ingly, of the four macroscopically 'normal' samples of
mucosa which were positive for pl5E-related mRNA, one
was histologically found to be suffering from non-specific
ulcerative colitis and two were afflicted by multiple polyps (of
the non-familial type). The remaining positive sample was
histologically normal as were all the other samples of macro-
scopically normal, pl5E-related negative colonic mucosa.
All four samples of gastric carcinoma tissue were positive
for p1SE mRNA on Northern blotting. Of the four corre-
sponding samples of macroscopically normal gastric mucosa,
only one was found to be positive and three negative. These
three samples were histologically normal but the sample of
positive 'normal' mucosa was the site of an active chronic
gastritis with metaplasia.
Effects ofFG-JO and FG-17 on lymphocyteproliferation
Both the FG-10 and FG-17 peptides produced inhibition of
the two-way MLR but this did not reach statistical signi-
Table III Relationship between Dukes' staging and p15E mRNA
positivity in primary colorectal cancers
Dukes' A Dukes' B Dukes' C Dukes' D
0/1 10/13 11/11 4/5
5 6 7 8
Figure 1 Representative Northern blots from samples of RNA isolates from four colorectal cancers and the corresponding normal
colonic mucosa from the same surgical specimen. Hybridisation was performed with the p1SE oligonucleotide probe described in
the text. Lanes 1, 3, 5 and 7 are samples isolated from colorectal cancer. Lanes 2, 4, 6 and 8 are samples removed from proximal
normal mucosa obtained from the paired surgical specimen, i.e. 1 & 2 were obtained from the same surgical specimen, as were 3 &
4, 5 & 6 and 7 & 8. Lanes 1, 5 and 7 were regarded as strongly positive. Lane 3 was regarded as weakly positive but this degree of
positivity was typical in that observed for those five samples of normal colonic mucosa which were regarded as being positive. All
other carcinoma specimens exhibited the same level of positive detection as seen in lanes 1, 5 and 7. All specimens designated as
being negative for pl5E mRNA gave blots identical with those in lanes 2, 4, 6 and 8.pl5E IN GASTROINTESTINAL CANCER 613
ficance until the concentrations of the peptides were 10- M
in culture (P<0.01, Student's t-test) (Figure 2). The concen-
tration of these two peptides required to induce statistically
significant (P<0.01) suppression of the proliferative res-
ponse to recombinant IL-2 was also 10-6M (Figure 3). In
contrast, both peptides consistently (P<0.01) inhibited anti-
CD3-induced lymphocyte proliferation at concentrations of
10-9M or more (Figure 4).
Effects ofFG-10 and FG-17 on polyclonal B-cell activation
Neither of the two synthetic peptides cause any detectable
inhibition of immunoglobulin production in response to
polyclonal activation with pokeweed mitogen. Indeed, at a
concentration of 10-6M peptides the amount of immuno-
globulin present in the supernatants of these polyclonally
activated B-cells was slightly but significantly elevated
(P<0.05, Figure 5).
Effects ofFG-10 and FG-17 on the generation oflymphokine-
activated killer (LAK) cells
As can be seen from the data shown in Figure 6, under the
conditions utilised in these experiments no inhibition of
either LAK cell generation or the lytic efficacy of unmodified
LAK cells was observed.
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Figure 2 Effects of different concentrations of the two synthetic
peptides of pl5E (FGIO - and FG17 1) on human lym-
phocyte proliferation in the two-way mixed lymphocyte reaction.
Vertical bars denote mean± standard error of 3H-Thymidine
uptake per well (n = 5), after 140 h of culture (*P<0.05).
Effects ofFG-10 and FG-17 on the neutrophil oxidative burst
Both peptides at a concentration of 10-6 M significantly sup-
pressed the basal, zymosan-activated and PMA-activated
neutrophil oxidative burst (P<0.05, Student's t-test (Figure
7)).
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Figure 4 Effects of different concentrations of the two synthetic
peptides of pl5E (FG1O - and FG17 M) on human lym-
phocyte proliferation induced by anti-CD3 monoclonal antibody.
Vertical bars denote mean± standard error of 3H-Thymidine
uptake per well (n = 5), after 96 h of culture (*P<0.05).
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Figure 5 Effects of different concentrations of the two synthetic
peptides of pl5E (FG1O _ and FG17 ) on polyclonal
B-cell activation induced by pokeweed mitogen. Vertical bars
denote mean±standard error of Ig content of supernatants from
PWM-activated human peripheral blood mononuclear cells
(*P<0.05).
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Figure 3 Effects of different concentrations of the two synthetic
peptides of pl5E (FGIO _ and FG17 m) on human lym-
phocyte proliferation induced by recombinant Interleukin-2. Ver-
tical bars denote mean±standard error of 3H-Thymidine uptake
per well (n = 5), after 96 h of culture (*P< 0.05).
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Figure 6 Effects of 10-6 M FG10 and FG17 on the induction of
LAK cytotoxicity in three separate experiments. Data are ex-
pressed as AUC (area under the curve) units for each experiment.
The data are linked for each individual experiment.
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Figure 7 Effects of control M 10 - M FGl0 _
, and FG17
E on basal, zymosan-induced and PMA-induced neutrophil
oxidative burst. Vertical bars denote mean ±standard error of
mean channel fluorescence obtained for the three separate
experiments (*P <0.05).
Discussion
Our experiments have revealed that the majority of human
colorectal and some gastric cancers contain cells which ex-
press RNA for a highly conserved retroviral sequence which
is known to possess immunosuppressive properties (Cianciolo
et al., 1985; Harrell et al., 1986; Ogasawara et al., 1988). The
size range of this sequence is consistent with that reported for
other endogenous retroviral products (Repaske et al., 1985).
In the colon the majority of the macroscopically normal
samples of mucosa failed to express plSE-relative mRNA. Of
the five samples of non-malignant colorectal mucosa which
were positive for plSE-related expression, four were histo-
logically abnormal, two being afflicted with inflammatory
bowel disease and two contained non-familial multiple
polyps. A similar pattern was obtained for the small number
of tissues obtained from the gastric cancer resectional speci-
mens with all the tumours being positive for pl5E-related
mRNA, the only macroscopically normal positive mucosa
being the seat of a severe chronic active gastritis with meta-
plasia.
The observations invite questions concerning the origin of
the plSE-related mRNA seen in these tumours. Certainly
plSE-related protein has been described in certain human
tumour cells and rodent tumour cell lines (Cianciolo et al.,
1983; 1984). In addition sera from patients with certain
haematopoietic malignancies contain a 74-kDa glycoprotein
which contains a plSE-related epitope again suggesting that
certain tumours of non-viral origin do express plSE-like
material (Jacquemin & Strijckmans, 1985). The possibility
that this material is expressed early during tumorigenesis
might explain the fact that mRNA for this protein was
observed in five out of six samples of non-malignant gast-
rointestinal mucosa, these five being histologically afflicted by
conditions known to be pre-malignant viz. inflammatory
bowel disease, colonic polyps, and gastritis with metaplasia.
On the other hand, it could be argued that the positive
isolates from the 'non-malignant' mucosae were due to con-
tamination by tumour cells in all but one instance (the colon
affected by Crohn's disease rather than malignant disease),
since both the malignant and non-malignant samples were
obtained from the same surgical specimens. However, we
endeavoured to minimise this possibility by removing the
'normal' intestinal mucosa at a site at least 10 cm from a
proximal site, away from the faecal stream.
An equally likely source for the p15E-like mRNA in these
tissue samples is of course the inflammatory cells which they
contain. It has been previously reported that murine mono-
clonal antibodies raised against an identical (but BSA-con-
jugated), peptide to FG-17 (CKS-17), have identified such
material in inflamed lymphoid tissue (Tas et al., 1991) and in
malignant and chronic inflammatory conditions of the naso-
oro-pharynx (Tan et al., 1987; Scheeren et al., 1992). The
latter study by Scheeren et al. (1992) is of particular interest
in that these authors were also unable to identify plSE-like
material in normal intestinal mucosa using the 4F5 and 19F8
monoclonal antibodies described by Cianciolo et al. (1983).
Antibodies to the CD4 epitope on human lymphocytes also
bind to CKS-17 (Rothman et al., 1990), but as yet there is no
data which suggest that the antibodies to CKS-17 can bind
to the CD4 molecule (TableI). However, only a small pro-
portion of the inflammatory cell infiltrate in colorectal cancer
is known to be CD4-positive, the majority being CD14-
positive monocytes (Allen & Hogg, 1987). However, this
latter observation presents us with further alternatives for
CKS-17 antibody binding partners.
A 10-amino acid sequence from interferon-a (INF-a) has
been identified which has a high level of sequence homology
with CKS-17 (TableI) (Ruegg & Strand, 1990). This appears
to be the smallest biologically active sequence of INF-a and
has similar immunosuppressive properties to those which we
describe here for our own synthetic peptides. CD14-positive
monocytes are a potent source of INF-a. Using a com-
puterised homology search we have found that there is a
sequence identity between our 10 amino acid peptide and a
sequence in tumour necrosis factor-a (TNF-x) (Table I).
Again monocytes are a major cell of origin of TNF-x which
has also been found to be present in colorectal cancer
(Beissert et al., 1989). However, these alternative proteins
which may cross-react with CKS-17 specific antibodies have
sufficiently different mRNA nucleotide sequences from pI5E
that they are very unlikely to hybridise with our oligo-
nucleotide probe under the hybridisation conditions em-
ployed.
Although we demonstrated the presence of plSE-related
mRNA at the site of colorectal and gastric cancers and in
some inflamed and pre-malignant sites in these organs, the
role of the proteins encoded by this endogenous message in
humans is unknown. To investigate this we therefore con-
structed two synthetic peptides, FG-10 and FG-17 (Table I)
which correspond to the endogenous p1 5E nucleotide se-
quence. At a concentration of 106M both these peptides
inhibited lymphocyte proliferation in mixed lymphocyte cul-
ture and in response to IL-2. Since the immunosuppressive
properties of FG-10 and FG-17 did not differ, the active
component must residue within the shorter ten amino acid
sequence. By means of peptide screening of uncoupled pep-
tides, Oostendorp et al. (1992) have recently described the
antilymphoproliferative properties of a LDLLFL sequence
which is fully contained in our FG-17 peptide but is only
partially represented in the FG-10 peptide. Suppression of
IL-2-induced proliferation occurred at identical concentra-
tions in culture to those seen with our own peptides. How-
ever, in our studies the inhibition of anti-CD3-induced T-cell
proliferation occurred at lower concentrations than those
required to inhibit the MLR or IL-2 induced lymphocyte
proliferation, suggesting that these peptides may specifically
suppress T-cell function through the CD3-T cell receptor
complex.
These peptides also inhibit the neutrophil oxidative burst.
The fact that intracellular signalling for PMA-stimulated
oxidative burst is mediated via protein phosphokinase C
whereas that for T-cell proliferation is via the phospha-
tidylinositol 4,5-biphosphate hydrolysis pathway suggests
that these peptides possess multiple mechanisms of action.
Like the fusion proteins ofHIV-1, these peptides may readily
insert into the lipid bilayer of the cell membrane and interfere
with a variety of ligand-induced signals. In contrast the lack
of activity of these peptides on LAK cell induction or PWM-
induced polyclonal immunoglobulin production suggests that
their mode of action may be more specific than appears at
first sight. It is also intriguing that our peptides exert their
immunosuppressive activities without having to be conjug-
ated to a carrier protein as was necessary for CKS-17 (Har-pl5E IN GASTROINTESTINAL CANCER 615
rell et al., 1986; Ogasawara et al., 1988; Nelson et al., 1989;
Nelson & Nelson, 1990). As yet we are unable to explain this
discrepancy.
Repaske et al. (1985) have described a full length endo-
genous human retroviral DNA which includes the code for a
ten amino acid sequence (Table I) simliar to the FG-10
sequence. Whether or not this sequence codes for a peptide
which possesses the same properties as FG-10 remains to be
investigated and raises the question of the function of such
sequences within the human genome. It is presumed that
endogenous pl5E-like proteins serve a useful purpose in
regulating the cellular immune response. In the murine
system p1SE has been shown to be an important component
of the inhibitory feedback circuit whose expression is induced
not only by immune stimuli but also by glucocorticoids
(Krieg et al., 1989; Helmberg et al., 1990). Since these
sequences are highly conserved amongst the murine, feline
and human species it is not unreasonable to suppose that
these events are common to all the species.
We have made the assumption that the amino acid
sequence constituting FG-10 is a functional component of a
protein with the same functional attributes which are not lost
during tertiary processing. Thus it might be argued that if the
specific mRNA is of leukocyte origin, these data do provide
evidence of the activation of an immune response against the
tumour within the primary site, the presence of pl5E-related
mRNA representing the negative feedback regulatory arc of
such a response. We are currently attempting to identify the
presence of pl5E-related mRNA in in vivo activated human
lymph nodes in an attempt to provide evidence for or against
this hypothesis. Conversely, the interaction of tumour cells
with the infiltrating inflammatory cells may cause the tumour
cells to produce immunoregulatory proteins, some of which
may provide a survival advantage for the tumour cells. The
outcome of this teleological argument must await the isola-
tion of the protein that is translated by the mRNA that our
oligonucleotide probes have identified and also immunohisto-
chemical studies of the expression and distribution of such
proteins using monoclonal antibodies which we are currently
developing for this purpose. However, as has been suggested
by others (Nelson et al., 1985; Lindvall et al., 1991), such
reagents may also become important therapeutic tools as
adjuncts to tumour immunotherapy in addition to providing
scientific explanations for the failure of immunotherapy in so
many instances.
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